prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
Company profile
Ticker
PROK
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • GE Vernova • Gilead Sciences • Apollo Global Management • ADT • Informatica • NIO • Opendoor • GoHealth • BrightSphere Investment ...
Former names
Social Capital Suvretta Holdings Corp. III
SEC CIK
Corporate docs
Subsidiaries
ProKidney Corp. GP Limited • ProKidney LP • ProKidney, LLC • ProKidney Acquisition Company, LLC ...
IRS number
981586514
PROK stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
3 Sep 24
10-Q
2024 Q2
Quarterly report
9 Aug 24
8-K
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
9 Aug 24
8-K
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
13 Jun 24
424B5
Prospectus supplement for primary offering
13 Jun 24
424B5
Prospectus supplement for primary offering
10 Jun 24
8-K
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
10 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
31 May 24
8-K
RMCL-002 Final Analysis Developing Solutions for Dialysis Prevention May 2024
29 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
Transcripts
Latest ownership filings
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
22 Oct 24
3
Aaron Cowen
22 Oct 24
SC 13G
BlackRock, Inc.
18 Oct 24
4
Darin J. Weber
20 Sep 24
144
Notice of proposed sale of securities
19 Sep 24
4
Bruce Culleton
16 Sep 24
4
Jennifer A. Fox
4 Sep 24
4
Todd C Girolamo
2 Aug 24
4
Darin J. Weber
29 Jul 24
SC 13D/A
Control Empresarial de Capitales S.A. de C.V.
25 Jun 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 214.51 mm | 214.51 mm | 214.51 mm | 214.51 mm | 214.51 mm | 214.51 mm |
Cash burn (monthly) | (no burn) | 2.42 mm | 14.35 mm | 12.83 mm | 12.76 mm | 10.18 mm |
Cash used (since last report) | n/a | 9.19 mm | 54.48 mm | 48.70 mm | 48.45 mm | 38.62 mm |
Cash remaining | n/a | 205.32 mm | 160.03 mm | 165.81 mm | 166.06 mm | 175.89 mm |
Runway (months of cash) | n/a | 84.8 | 11.2 | 12.9 | 13.0 | 17.3 |
Institutional ownership, Q2 2024
77.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 59 |
Closed positions | 2 |
Increased positions | 6 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 99.13 bn |
Total shares | 222.98 mm |
Total puts | 117.60 k |
Total calls | 644.00 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Tolerantia | 111.26 mm | $330.44 mm |
Carso, S.A. de C.V. Inversora | 71.56 mm | $173.18 mm |
MS Morgan Stanley | 14.45 mm | $35.54 bn |
Suvretta Capital Management | 9.34 mm | $22.98 bn |
Vanguard | 3.98 mm | $9.78 bn |
BLK BlackRock | 3.66 mm | $8.99 bn |
Bleichroeder | 2.61 mm | $6.43 bn |
STT State Street | 1.23 mm | $3.02 bn |
Geode Capital Management | 1.09 mm | $2.68 bn |
Brown University | 1.00 mm | $2.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Sep 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 2.5 | 16,412 | 41.03 k | 103,480 |
13 Sep 24 | Bruce Culleton | Employee stock option Class A Ordinary Shares | Grant | Acquire A | No | No | 1.69 | 500,000 | 845.00 k | 500,000 |
3 Sep 24 | Jennifer A. Fox | Director stock option Class A Ordinary Shares | Grant | Acquire A | No | No | 2.4 | 9,535 | 22.88 k | 9,535 |
31 Jul 24 | Todd C Girolamo | Class A Ordinary Shares | Conversion | Acquire C | No | No | 0 | 81,928 | 0.00 | 163,856 |
31 Jul 24 | Todd C Girolamo | Common Units in ProKidney LP Class A Ordinary Shares | Conversion | Dispose C | No | No | 0 | 81,928 | 0.00 | 163,857 |
31 Jul 24 | Todd C Girolamo | Class B Ordinary Shares Class A Ordinary Shares | Conversion | Dispose C | No | No | 0 | 81,928 | 0.00 | 163,857 |
News
ProKidney to Present Cell Therapy Data for CKD at ASN Kidney Week 2024
14 Oct 24
JP Morgan Initiates Coverage On ProKidney with Neutral Rating
30 Sep 24
Guggenheim Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $6
10 Sep 24
B of A Securities Maintains Neutral on ProKidney, Lowers Price Target to $3
4 Sep 24
ProKidney Decides To Prioritize PROACT 1; Plans To Discontinue PROACT 2, Which Was Focused On Enrollment Outside US; Now Expects Current Cash To Support Operating Plans Into Q1 2027
3 Sep 24
Press releases
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024
14 Oct 24
ProKidney to Participate in the UBS Virtual Organ Restoration Day
9 Oct 24
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.
3 Sep 24
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
27 Aug 24
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
9 Aug 24